Neuphoria Therapeutics (NEUP) Receivables - Net (2020 - 2026)

Neuphoria Therapeutics (NEUP) has reported Receivables - Net for 7 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Receivables - Net rose 6427.9% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 6427.9% increase from a year earlier, with the FY2025 full-year figure at $11948.0, down 90.58% from the prior year.
• Receivables - Net was $1.6 million for Q1 2026 at Neuphoria Therapeutics, up from $1.1 million in the prior quarter.
• Over five years, Receivables - Net peaked at $1.6 million in Q1 2026 and troughed at $1758.0 in Q3 2025.
• A 5-year average of $308788.7 and a median of $40830.0 in 2022 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net sank 98.48% in 2025 and surged 6427.9% in 2026, its largest moves.
• Over 5 years, Receivables - Net stood at $46099.0 in 2022, then slumped by 78.66% to $9836.9 in 2023, then jumped by 261.51% to $35561.0 in 2024, then jumped by 3021.14% to $1.1 million in 2025, then soared by 44.64% to $1.6 million in 2026.
• The last three Receivables - Net figures came in at $1.6 million (Q1 2026), $1.1 million (Q4 2025), and $1758.0 (Q3 2025), per Business Quant data.